bioMérieux – First-Half 2021 Results

  • €1,574 million in first-half 2021 sales, up 12.3% like-for-like
  • Q2 sales organic growth at 7.9% in line with our expectations: slowdown in molecular biology, strong growth of immunoassays, and good momentum in microbiology and industrial applications
  • Contributive operating income before non-recurring items up 48% to €374 million, or nearly 24 % of sales for the first half of the year
  • 2021 guidance confirmation:

    bioMérieux confirms its annual guidance of organic sales growth at neutral to mid-single digit rate and contributive operating income before non-recurring items in line with 2020.

    Contact us